Aimee Nguyen, MD
Urogynecology and Reconstructive Pelvic Surgery · Frisco, TXNPI 1104042464
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,542 of the $4,440 with a category attached, or 79.8%. It is spread thinly across 20 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,770 and has fallen 74.8% since, to $446 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in TX, where the typical reported total is $5,014.
Across 144 payments — averaging $30.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$858
- Astellas Pharma US Inc$744
- AbbVie$608
- Axonics, Inc.$594
- Femselect Inc.$342
- Sumitomo Pharma America, Inc.$328
- plus $967 from 14 others
What the payments were for
- Travel & lodging$64515%
- Food & beverage$3,54280%
- Education$2536%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 9 | $858 |
| Astellas Pharma US Inc | 33 | $744 |
| AbbVie(2 entities) | 27 | $608 |
| Axonics, Inc. | 24 | $594 |
| Femselect Inc. | 1 | $342 |
| Sumitomo Pharma America, Inc. | 13 | $328 |
| Boston Scientific | 9 | $242 |
| Urovant Sciences Inc | 10 | $209 |
| Antares Pharma, Inc. | 6 | $120 |
| Medtronic | 1 | $105 |
| Avation Medical, Inc. | 1 | $97 |
| Caldera Medical, Inc | 2 | $35 |
| Vertex | 1 | $26 |
| Davol Inc. | 1 | $24 |
| BD | 1 | $21 |
| Pfizer | 1 | $19 |
| Bluewind Medical | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,440 in reported general payments places this provider in the 45th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 68 | $68,760 |
| GemtesaVibegron | 50 | $65,602 |
| Mirabegron ErMirabegron | 16 | $12,936 |
| Trospium Chloride | 74 | $3,463 |
| Estradiol | 41 | $3,106 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 208 | $1,969 |
| Methenamine Hippurate | 16 | $1,350 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $372 |
| Ibuprofen | 61 | $204 |
| Clobetasol Propionate | 14 | $175 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $105 |
| Tamsulosin Hcl | 12 | $86 |
| Metronidazole | 11 | $65 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 15 | $55 |
| Cephalexin | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $744 | $68,76068 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $328 | $65,60250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Frisco
- Stephen KrausSan Antonio$372K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Tracy Cannon-SmithArlington$29K
- Teresa IrwinSan Marcos$20K
- Oluwarotimi NetteyHouston$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.